Terms: = Germ cell tumor AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Clinical Outcome
17 results:
1. Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor outcome in Male Malignant germ cell tumors.
Timmerman DM; Eleveld TF; Sriram S; Dorssers LCJ; Gillis AJM; Schmidtova S; Kalavska K; van de Werken HJG; Oing C; Honecker F; Mego M; Looijenga LHJ
J Clin Oncol; 2022 Sep; 40(26):3077-3087. PubMed ID: 35442716
[TBL] [Abstract] [Full Text] [Related]
2. p53 and mdm2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome.
Lobo J; Alzamora MA; Guimarães R; Cantante M; Lopes P; Braga I; Maurício J; Jerónimo C; Henrique R
Andrology; 2020 Sep; 8(5):1233-1242. PubMed ID: 32384200
[TBL] [Abstract] [Full Text] [Related]
3. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large cell Neuroendocrine Carcinomas with Distinct Prognosis.
Milione M; Maisonneuve P; Grillo F; Mangogna A; Centonze G; Prinzi N; Pusceddu S; Garzone G; Cattaneo L; Busico A; Bossi P; Spaggiari P; Pellegrinelli A; Del Gobbo A; Ferrero S; Kankava K; Pruneri G; Rolli L; Roca E; Bercich L; Tironi A; Benvenuti MR; Gallazzi MS; Romano R; Berruti A; Pastorino U; Capella C
Neuroendocrinology; 2021; 111(5):475-489. PubMed ID: 32365350
[TBL] [Abstract] [Full Text] [Related]
4. Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review.
Romano FJ; Rossetti S; Conteduca V; Schepisi G; Cavaliere C; Di Franco R; La Mantia E; Castaldo L; Nocerino F; Ametrano G; Cappuccio F; Malzone G; Montanari M; Vanacore D; Quagliariello V; Piscitelli R; Pepe MF; Berretta M; D'Aniello C; Perdonà S; Muto P; Botti G; Ciliberto G; Veneziani BM; De Falco F; Maiolino P; Caraglia M; Montella M; De Giorgi U; Facchini G
Oncotarget; 2016 Dec; 7(51):85641-85649. PubMed ID: 27821802
[TBL] [Abstract] [Full Text] [Related]
5. Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma.
Tzaridis T; Milde T; Pajtler KW; Bender S; Jones DT; Müller S; Wittmann A; Schlotter M; Kulozik AE; Lichter P; Peter Collins V; Witt O; Kool M; Korshunov A; Pfister SM; Witt H
Oncotarget; 2016 Sep; 7(38):61860-61873. PubMed ID: 27556362
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic significance of mdm2 gene expression in childhood neuroblastoma.
Inomistova MV; Svergun NM; Khranovska NM; Skachkova OV; Gorbach OI; Klymnyuk GI
Exp Oncol; 2015 Jun; 37(2):111-5. PubMed ID: 26112937
[TBL] [Abstract] [Full Text] [Related]
7. Lack of association between mdm2 promoter SNP309 and clinical outcome in patients with neuroblastoma.
Rihani A; Van Maerken T; De Wilde B; Zeka F; Laureys G; Norga K; Tonini GP; Coco S; Versteeg R; Noguera R; Schulte JH; Eggert A; Stallings RL; Speleman F; Vandesompele J
Pediatr Blood Cancer; 2014 Oct; 61(10):1867-70. PubMed ID: 24391119
[TBL] [Abstract] [Full Text] [Related]
8. In human retinoblastoma Y79 cells okadaic acid-parthenolide co-treatment induces synergistic apoptotic effects, with PTEN as a key player.
Di Fiore R; Drago-Ferrante R; D'Anneo A; Augello G; Carlisi D; De Blasio A; Giuliano M; Tesoriere G; Vento R
Cancer Biol Ther; 2013 Oct; 14(10):922-31. PubMed ID: 23938948
[TBL] [Abstract] [Full Text] [Related]
9. Functional polymorphisms associated with disease-free survival in resected carcinoma of the esophagus.
Boonstra JJ; van Marion R; Tilanus HW; Dinjens WN
J Gastrointest Surg; 2011 Jan; 15(1):48-56. PubMed ID: 20922573
[TBL] [Abstract] [Full Text] [Related]
10. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
[TBL] [Abstract] [Full Text] [Related]
12. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.
Jönsson G; Dahl C; Staaf J; Sandberg T; Bendahl PO; Ringnér M; Guldberg P; Borg A
Oncogene; 2007 Jul; 26(32):4738-48. PubMed ID: 17260012
[TBL] [Abstract] [Full Text] [Related]
13. Immunohistochemical markers for prognosis of oligodendroglial neoplasms.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):237-53. PubMed ID: 12187958
[TBL] [Abstract] [Full Text] [Related]
14. Immunohistochemical markers for prognosis of cerebral glioblastomas.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):217-36. PubMed ID: 12187957
[TBL] [Abstract] [Full Text] [Related]
15. p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease.
Omura-Minamisawa M; Diccianni MB; Chang RC; Batova A; Bridgeman LJ; Schiff J; Cohn SL; London WB; Yu AL
Clin Cancer Res; 2001 Nov; 7(11):3481-90. PubMed ID: 11705866
[TBL] [Abstract] [Full Text] [Related]
16. The prognostic value of cyclin D1, p53, and mdm2 protein expression in uveal melanoma.
Coupland SE; Anastassiou G; Stang A; Schilling H; Anagnostopoulos I; Bornfeld N; Stein H
J Pathol; 2000 Jun; 191(2):120-6. PubMed ID: 10861569
[TBL] [Abstract] [Full Text] [Related]
17. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, mdm2 or Bcl-2 genes.
Newcomb EW; Cohen H; Lee SR; Bhalla SK; Bloom J; Hayes RL; Miller DC
Brain Pathol; 1998 Oct; 8(4):655-67. PubMed ID: 9804374
[TBL] [Abstract] [Full Text] [Related]
